Supplementary Online Content

Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. *JAMA Dermatol*. Published online September 23, 2020. doi:10.1001/jamadermatol.2020.3238

eAppendix. Investigator List

eTable. Statistical Analyses of Percentage of Participants with Complete Clearance of all Baseline and New Lesions

This supplementary material has been provided by the authors to give readers additional information about their work

eAppendix. Investigator List

The authors acknowledge the valuable contributions made by the VP-102 Phase 3 trial investigators and their staff (CAMP-1 and CAMP-2 in alphabetical order):

Claude Ashley, Jr., MD (Southeastern Pediatric Associates); Rania Agha, MD (Summit Dermatology); Joshua Berlin, MD (Study Protocol, Inc.); Bradford Brabec, MD (Midwest Children's Health); Paul Bernhardson, MD (Midwest Children's Health—North); David Brougher, MD (Pedia Research); Suzanne Bruce, MD (Center for Skin Research); Lawrence Eichenfield, MD (Rady Children's Hospital); Ana Elosegui, MD (Lenus Research and Medical Group); Nicole George, MD (Pediatric Associates of Fairfield); Mercedes Gonzalez, MD (Skin Research Institute); Ashvin Garlapati, MD (Dermatology Center of Northwestern Indiana); Fasahat Hamzavi, MD (Hamzavi Dermatology); Caroll Howard, MD (Pedia Research); Jeanette Jakus, MD (Kings County Hospital); Imad Jandali, MD (ASCLEPES Research Center); William Johnston, MD (Alabama Clinical Therapeutics); Scott Katz, MD (ACRC Trials, Plano Pediatrics); Pearl Kwong, MD (Solutions Through Advanced Research); Joseph Ley, MD (Holston Medical Group); Aida Lugo-Somolinos, MD (UNC Dermatology Center); Andrea Mabry, MD (Applied Research Center of Arkansas); Darvy Mann, MD (DCOL Center for Clinical Research); Wendy McFalda, MD (Clarkston Skin Research); Angela Moore, MD (Arlington Research Center); Amy Paller, MD (Northwestern Memorial Hospital); Kappa Peddy, MD (The Education and Research Foundation); Blakely Richardson, MD (Tekton Research); Elaine Siegfried, MD (St Louis Children's Hospital); Jeffrey Sugarman, MD (Redwood Family Dermatology); Matthew Zook, MD (Olympian Clinical Research).

eTable. Statistical Analyses of Percentage of Participants with Complete Clearance of all Baseline and New Lesions

CAMP-1	**Pierson χ2 p-value***	**Logistical Regression p-value****
Day 21/Visit 2	0.0302	0.0443
Day 42/Visit 3	0.0152	0.0209
Day 63/Visit 4	0.0067	0.0086
Day 84/EOS	<0.0001	<0.0001
CAMP-2	**Pierson χ2 p-value***	**Logistical Regression p-value****
Day 21/Visit 2	0.1382	0.2100
Day 42/Visit 3	0.0101	0.0178
Day 63/Visit 4	<0.0001	<0.0001
Day 84/EOS	<0.0001	<0.0001

*Pre-specified analysis using Pierson χ^2 test

**Post-hoc analysis of Logistical Regression controlling for baseline lesion count

P-values were similar between pre-specified statistical analyses and post-hoc analyses controlling for baseline lesion count in the percentage of participants with complete clearance at each time point/visit.